MAZE Insider Trading Activity and SEC Form 4 Filings
MAZE insider trading summary
Over the past 12 months, insiders at Maze Therapeutics, Inc. (MAZE) reported 88 sales worth $21.6M by 6 insiders and no open-market purchases on SEC Form 4. Net insider selling was $21.6M.
Latest MAZE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2026 | Jason V Coloma | Chief Executive Officer | Sell | $799K (26,563 @ $30.09) |
| Nov 2, 2026 | Jason V Coloma | Chief Executive Officer | Sell | $166K (5,345 @ $31.05) |
| Nov 2, 2026 | Jason V Coloma | Chief Executive Officer | Sell | $10K (336 @ $30.91) |
| Nov 2, 2026 | Jason V Coloma | Chief Executive Officer | Sell | $68K (2,257 @ $30.12) |
| Oct 29, 2026 | Atul Dandekar | Csbo | Sell | $241K (7,500 @ $32.07) |
| Oct 1, 2026 | Jason V Coloma | Chief Executive Officer | Sell | $862K (31,908 @ $27.02) |
| Oct 1, 2026 | Harold Bernstein | President, R&D & CMO | Sell | $435K (16,141 @ $26.93) |
| Oct 1, 2026 | Jason V Coloma | Chief Executive Officer | Sell | $70K (2,593 @ $27.02) |
| Sep 29, 2026 | Atul Dandekar | Csbo | Sell | $203K (7,500 @ $27.06) |
| Sep 4, 2026 | Harold Bernstein | President, R&D & CMO | Sell | $255K (9,705 @ $26.22) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.